Adlai Nortye (ANL) Other Non-Current Assets (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Other Non-Current Assets of $31.8 million for Q2 2024, up 28.17% quarter-over-quarter from $24.8 million in Q4 2023.
Analysis
Adlai Nortye (ANL) Other Non-Current Assets (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Other Non-Current Assets for 3 consecutive years, with $31.8 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Other Non-Current Assets changed N/A year-over-year to $31.8 million; the TTM figure through Jun 2024 stood at $31.8 million (changed N/A YoY), while the FY2023 annual figure was $24.8 million, up 7499.08% from the prior year.
- Other Non-Current Assets improved to $31.8 million in Q2 2024 per ANL's latest filing, from $24.8 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $31.8 million in Q2 2024 and bottomed at $327000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $19.0 million across 3 years, with a median of $24.8 million in 2023.
- On a YoY basis, Other Non-Current Assets climbed as much as 7499.08% in 2023 and fell as far as 7499.08% in 2023.
- Adlai Nortye's Other Non-Current Assets stood at $327000.0 in 2022, then surged by 7499.08% to $24.8 million in 2023, then advanced by 28.17% to $31.8 million in 2024.
- Business Quant data shows ANL's Other Non-Current Assets at $31.8 million in Q2 2024, $24.8 million in Q4 2023, and $327000.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 80,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 80,000.00 |
| Dec 31, 2025 | 15.73 Mn |
| Jun 30, 2025 | 18.24 Mn |
| Dec 31, 2023 | 252.81 Mn |
| Dec 31, 2022 | 210.04 Mn |